Our most-read glaucoma coverage of 2025 reflects an ongoing shift in how clinicians approach initial treatment and long-term disease control. From expert discussions weighing topical therapy against earlier procedural intervention to data comparing MIGS devices and commentary on the real-world impact of noncompliance, these highlights underscore a growing focus on durable, patient-centered glaucoma management.
First-line Therapies for Glaucoma: Topical Drops vs. Procedures
Christine Funke, MD; Brian Shafer, MD; and J. Morgan Micheletti, MD, talk about optimal first-line treatment for glaucoma and how to introduce a more interventional approach in this engaging podcast episode.
Listen to the full podcast here.
Noncompliance with topical medical therapy: why it matters and what we can do about it
This editorial highlights the widespread gap between clinical trial efficacy and real-world outcomes in ophthalmology, driven largely by poor patient adherence to topical therapies due to physical, cognitive, financial, and regimen-related barriers. John A. Hovanesian, MD outlines practical strategies and emerging alternatives—such as simplified regimens, sustained-release drug delivery, and procedural interventions—to reduce reliance on patient compliance and improve treatment outcomes.
Read the full article here.
AGS 2025: A study compared two MIGS devices, iStent infinite and Hydrus Microstent
George Reiss, MD, of Eye Physicians & Surgeons of Arizona, discusses a study he presented at the 2025 American Glaucoma Society (AGS) Annual Meeting that compared use of iStent infinite versus Hydrus Microstent for glaucoma.
Watch the full video here.
Related Content
